Formulary Chapter 13: Skin - Full Chapter
|
13.08.01 |
Sunscreen preparations |
|
|
|
- Sunscreen preparations are regarded as drugs when prescribed for skin protection against ultraviolet radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photodermatoses, including vitiligo, those resulting from radiotherapy and chronic or recurrent herpes simplex labialis.
- Prescriptions used in this way should be marked "ACBS" (Advisory Committee on Borderline Substances).
|
|
Diclofenac Sodium 3% gel (Solaraze®)

|
Non Formulary
|
Not recommended due to lack of evidence. |
Imiquimod 3.75% cream (Zyclara®) (Actinic Keratosis)

|
Non Formulary
|
Not recommended due to insufficient evidence of advantage over other treatment options or cost efficacy. APCO May 2007. |
Ingenol mebutate (Picato®)

|
Non Formulary
|
Not included in Solar Keratosis guidelines in line with MHRA warning
|
Key |
|
|
Cytotoxic Drug
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
Status |
Description |

|
Red: Medicines which should only be prescribed in secondary care by a specialist. |

|
Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred. |

|
Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO). |

|
Green: Medicines which are suitable for initiation and ongoing prescribing within primary care. |

|
Brown: Medicines which should only be prescribed in restricted circumstances. |

|
Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety. |

|
not used |
|
|